Calidi Biotherapeutics, Inc. (CLDWW) — 8-K Filings

8-K Filings (50)

• 8-K Filing — Nov 10, 2025
• 8-K Filing — Oct 31, 2025
• Calidi Biotherapeutics Files 8-K — Oct 24, 2025 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on October 24, 2025, reporting on events that occurred on October 22, 2025. The filing includes a Regulation FD Disclo
• Calidi Biotherapeutics Announces Director Changes and Agreements — Sep 19, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. announced on August 8, 2025, the departure of Director Dr. Jonathan R. Roth and the appointment of Dr. Michael J. Ybarra as a new d
• Calidi Biotherapeutics to Raise $10M in Direct Offering — Aug 29, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. reported on August 29, 2025, that it has entered into a securities purchase agreement. The company plans to issue and sell approxim
• Calidi Biotherapeutics Signs Material Definitive Agreement — Aug 22, 2025 Risk: medium
  On August 20, 2025, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company, formerly known as First Light Acquisition Group, Inc
• Calidi Biotherapeutics Appoints New CMO, Director — Aug 14, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. announced on August 8, 2025, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer and the election of Mr. David M. R.
• Calidi Biotherapeutics Files 8-K on Financials — Aug 8, 2025 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on August 8, 2025, reporting on its results of operations and financial condition, as well as providing a Regulation F
• Calidi Biotherapeutics Files 8-K on Security Holder Rights — Aug 7, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. filed an 8-K on August 7, 2025, reporting material modifications to the rights of security holders and amendments to its articles o
• Calidi Biotherapeutics Announces Corporate Changes — Jul 25, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. announced on July 24, 2025, a series of significant corporate actions. These include the election of new directors, the appointment
• Calidi Biotherapeutics Reports Shareholder Vote — Jul 11, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. filed an 8-K on July 11, 2025, reporting on a matter submitted to a vote of security holders on July 9, 2025. The filing does not s
• Calidi Biotherapeutics Files 8-K with Material Agreements — Jul 10, 2025 Risk: medium
  On July 9, 2025, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities a
• Calidi Biotherapeutics Changes Certifying Accountant — May 2, 2025 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on May 2, 2025, reporting a change in its certifying accountant as of April 30, 2025. The company, formerly known as F
• Calidi Biotherapeutics Appoints New CMO, Director — Apr 23, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. announced on April 17, 2025, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer and the election of Mr. David M. E.
• Calidi Biotherapeutics Files 8-K with Financials — Apr 10, 2025 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on April 10, 2025, reporting an event on April 8, 2025. The filing indicates a Regulation FD Disclosure and includes F
• Calidi Biotherapeutics Files 8-K: Material Agreement & Equity Sales — Apr 1, 2025 Risk: medium
  On March 28, 2025, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
• Calidi Biotherapeutics Files 8-K on Financials — Mar 31, 2025 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on March 31, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Finan
• 8-K Filing — Mar 10, 2025
• Calidi Biotherapeutics, Inc. Files 8-K — Feb 5, 2025 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on February 5, 2025, reporting an event on February 4, 2025. The filing indicates a change in the company's former nam
• Calidi Biotherapeutics Terminates Material Agreement — Jan 28, 2025 Risk: medium
  Calidi Biotherapeutics, Inc. announced on January 23, 2025, the termination of a material definitive agreement. The company also provided updates on its results
• Calidi Biotherapeutics Files 8-K — Jan 10, 2025 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on January 10, 2025, reporting other events and financial statements. The company, formerly known as First Light Acqui
• Calidi Biotherapeutics Files 8-K Report — Nov 18, 2024 Risk: low
  On November 18, 2024, Calidi Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhi
• Calidi Biotherapeutics Files 8-K: Material Agreement & Equity Sales — Nov 15, 2024 Risk: medium
  On November 14, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
• Calidi Biotherapeutics Files 8-K on Financials — Nov 13, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition as of November 12, 2024. The fili
• Calidi Biotherapeutics Files 8-K for Equity Sales — Oct 24, 2024 Risk: medium
  On October 23, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company,
• Calidi Biotherapeutics Faces Delisting Concerns — Oct 18, 2024 Risk: high
  Calidi Biotherapeutics, Inc. filed an 8-K on October 17, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was f
• Calidi Biotherapeutics Files 8-K: Material Agreement — Oct 11, 2024 Risk: medium
  On October 11, 2024, Calidi Biotherapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements a
• Calidi Biotherapeutics Files 8-K — Sep 30, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on September 30, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, for
• Calidi Biotherapeutics Files 8-K on Security Holder Vote Matters — Sep 24, 2024 Risk: medium
  On September 20, 2024, Calidi Biotherapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The company, form
• Calidi Biotherapeutics Files 8-K — Sep 12, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on September 11, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, former
• Calidi Biotherapeutics Files 8-K — Aug 22, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on August 22, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Calidi Biotherapeutics Appoints New CMO, Adds Director — Aug 20, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. announced on August 16, 2024, the appointment of Dr. Xiaolin Liu as Chief Medical Officer and the election of Dr. Lawrence Stern to
• Calidi Biotherapeutics Files 8-K on Financials — Aug 14, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing also includes Regulatio
• Calidi Biotherapeutics Files 8-K on Equity Sales — Jul 29, 2024 Risk: medium
  On July 26, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, for
• Calidi Biotherapeutics Files 8-K for Bylaws and Financials — Jul 15, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on July 15, 2024, reporting events that occurred on July 10, 2024. The filing primarily concerns amendments to its art
• Calidi Biotherapeutics Enters Loan Agreement — Jul 8, 2024 Risk: medium
  On July 1, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement, specifically a loan and security agreement with an unnamed lender. T
• Calidi Biotherapeutics Files 8-K — Jul 5, 2024 Risk: low
  On July 5, 2024, Calidi Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. It
• Calidi Biotherapeutics Appoints New CMO, Director — Jun 26, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. announced on June 20, 2024, the appointment of Dr. Xiaolin Liu as Chief Medical Officer and the election of Dr. Lawrence E. Stern t
• Calidi Biotherapeutics Files 8-K on Shareholder Votes and Exhibits — Jun 12, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits as of
• Calidi Biotherapeutics Files 8-K with Material Agreements — Jun 4, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. entered into a material definitive agreement on June 3, 2024. The company also reported on unregistered sales of equity securities
• Calidi Biotherapeutics Files 8-K: Material Agreement & Equity Sales — May 31, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. announced on May 31, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of e
• Calidi Biotherapeutics Announces CFO Departure, Board Changes — May 17, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. announced on May 13, 2024, the departure of its Chief Financial Officer, Jonathan R. Moreland. The company also reported the electi
• Calidi Biotherapeutics Announces Board and Executive Changes — May 16, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. announced on May 10, 2024, changes in its board of directors and executive compensation. Specifically, the company elected Dr. Jona
• Calidi Biotherapeutics Secures $10M Private Placement — May 15, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. announced on May 14, 2024, that it has entered into a securities purchase agreement for a private placement of approximately $10.0
• Calidi Biotherapeutics Signs Material Definitive Agreement — Apr 19, 2024 Risk: medium
  On April 14, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company, formerly known as First Light Acquisition Group, Inc.
• Calidi Biotherapeutics Enters Material Definitive Agreement — Apr 18, 2024 Risk: medium
  On April 14, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement. The company, formerly known as First Light Acquisition Group, Inc.
• Calidi Biotherapeutics Files 8-K on Financials — Mar 18, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on March 18, 2024, reporting on its results of operations and financial condition as of March 15, 2024. The filing als
• Calidi Biotherapeutics Files 8-K: Agreement Termination & New Obligations — Mar 12, 2024 Risk: medium
  Calidi Biotherapeutics, Inc. announced on March 8, 2024, the termination of a material definitive agreement and entered into a new direct financial obligation.
• Calidi Biotherapeutics Files 8-K for Bylaw Amendments & Financials — Mar 1, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on February 28, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The co
• Calidi Biotherapeutics Updates Public on Stock and Warrants — Feb 28, 2024 Risk: low
  Calidi Biotherapeutics, Inc. filed an 8-K on February 28, 2024, disclosing information under Regulation FD and regarding financial statements and exhibits. The

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX